Global Primary Immunodeficiency Therapeutic Market Research Report 2024

Report ID: 1843285 | Published Date: Jan 2025 | No. of Page: 88 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Immunoglobulin Replacement Therapy
        1.2.3 Stem Cell or Bone Marrow Transplantation
        1.2.4 Antibiotic Therapy
        1.2.5 Gene Therapy
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Primary Immunodeficiency Therapeutic Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Antibody Deficiency
        1.3.3 Cellular Immunodeficiency
        1.3.4 Innate Immune Disorders
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Primary Immunodeficiency Therapeutic Market Perspective (2017-2028)
    2.2 Primary Immunodeficiency Therapeutic Growth Trends by Region
        2.2.1 Primary Immunodeficiency Therapeutic Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Primary Immunodeficiency Therapeutic Historic Market Size by Region (2017-2022)
        2.2.3 Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2023-2028)
    2.3 Primary Immunodeficiency Therapeutic Market Dynamics
        2.3.1 Primary Immunodeficiency Therapeutic Industry Trends
        2.3.2 Primary Immunodeficiency Therapeutic Market Drivers
        2.3.3 Primary Immunodeficiency Therapeutic Market Challenges
        2.3.4 Primary Immunodeficiency Therapeutic Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Primary Immunodeficiency Therapeutic Players by Revenue
        3.1.1 Global Top Primary Immunodeficiency Therapeutic Players by Revenue (2017-2022)
        3.1.2 Global Primary Immunodeficiency Therapeutic Revenue Market Share by Players (2017-2022)
    3.2 Global Primary Immunodeficiency Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Primary Immunodeficiency Therapeutic Revenue
    3.4 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio
        3.4.1 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Primary Immunodeficiency Therapeutic Revenue in 2021
    3.5 Primary Immunodeficiency Therapeutic Key Players Head office and Area Served
    3.6 Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
    3.7 Date of Enter into Primary Immunodeficiency Therapeutic Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Immunodeficiency Therapeutic Breakdown Data by Type
    4.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Type (2017-2022)
    4.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2023-2028)
5 Primary Immunodeficiency Therapeutic Breakdown Data by Application
    5.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Application (2017-2022)
    5.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Primary Immunodeficiency Therapeutic Market Size (2017-2028)
    6.2 North America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
    6.3 North America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Primary Immunodeficiency Therapeutic Market Size (2017-2028)
    7.2 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
    7.3 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size (2017-2028)
    8.2 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
    8.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Primary Immunodeficiency Therapeutic Market Size (2017-2028)
    9.2 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
    9.3 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size (2017-2028)
    10.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
    10.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Baxter International
        11.1.1 Baxter International Company Detail
        11.1.2 Baxter International Business Overview
        11.1.3 Baxter International Primary Immunodeficiency Therapeutic Introduction
        11.1.4 Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.1.5 Baxter International Recent Development
    11.2 Takeda Pharmaceutical
        11.2.1 Takeda Pharmaceutical Company Detail
        11.2.2 Takeda Pharmaceutical Business Overview
        11.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Introduction
        11.2.4 Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.2.5 Takeda Pharmaceutical Recent Development
    11.3 CSL Limited
        11.3.1 CSL Limited Company Detail
        11.3.2 CSL Limited Business Overview
        11.3.3 CSL Limited Primary Immunodeficiency Therapeutic Introduction
        11.3.4 CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.3.5 CSL Limited Recent Development
    11.4 Octapharma
        11.4.1 Octapharma Company Detail
        11.4.2 Octapharma Business Overview
        11.4.3 Octapharma Primary Immunodeficiency Therapeutic Introduction
        11.4.4 Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.4.5 Octapharma Recent Development
    11.5 Kedrion Biopharma
        11.5.1 Kedrion Biopharma Company Detail
        11.5.2 Kedrion Biopharma Business Overview
        11.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Introduction
        11.5.4 Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.5.5 Kedrion Biopharma Recent Development
    11.6 Bio Products Laboratory
        11.6.1 Bio Products Laboratory Company Detail
        11.6.2 Bio Products Laboratory Business Overview
        11.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Introduction
        11.6.4 Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.6.5 Bio Products Laboratory Recent Development
    11.7 LFB group
        11.7.1 LFB group Company Detail
        11.7.2 LFB group Business Overview
        11.7.3 LFB group Primary Immunodeficiency Therapeutic Introduction
        11.7.4 LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.7.5 LFB group Recent Development
    11.8 Grifols
        11.8.1 Grifols Company Detail
        11.8.2 Grifols Business Overview
        11.8.3 Grifols Primary Immunodeficiency Therapeutic Introduction
        11.8.4 Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.8.5 Grifols Recent Development
    11.9 Lupin Pharmaceuticals
        11.9.1 Lupin Pharmaceuticals Company Detail
        11.9.2 Lupin Pharmaceuticals Business Overview
        11.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Introduction
        11.9.4 Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
        11.9.5 Lupin Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Immunoglobulin Replacement Therapy
    Table 3. Key Players of Stem Cell or Bone Marrow Transplantation
    Table 4. Key Players of Antibiotic Therapy
    Table 5. Key Players of Gene Therapy
    Table 6. Key Players of Others
    Table 7. Global Primary Immunodeficiency Therapeutic Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Primary Immunodeficiency Therapeutic Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Primary Immunodeficiency Therapeutic Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Primary Immunodeficiency Therapeutic Market Share by Region (2017-2022)
    Table 11. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Primary Immunodeficiency Therapeutic Market Share by Region (2023-2028)
    Table 13. Primary Immunodeficiency Therapeutic Market Trends
    Table 14. Primary Immunodeficiency Therapeutic Market Drivers
    Table 15. Primary Immunodeficiency Therapeutic Market Challenges
    Table 16. Primary Immunodeficiency Therapeutic Market Restraints
    Table 17. Global Primary Immunodeficiency Therapeutic Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Primary Immunodeficiency Therapeutic Market Share by Players (2017-2022)
    Table 19. Global Top Primary Immunodeficiency Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2021)
    Table 20. Ranking of Global Top Primary Immunodeficiency Therapeutic Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Primary Immunodeficiency Therapeutic Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
    Table 24. Date of Enter into Primary Immunodeficiency Therapeutic Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2017-2022)
    Table 28. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2023-2028)
    Table 30. Global Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2017-2022)
    Table 32. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2023-2028)
    Table 34. North America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 35. North America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 37. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2017-2022) & (US$ Million)
    Table 39. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2023-2028) & (US$ Million)
    Table 40. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Baxter International Company Detail
    Table 45. Baxter International Business Overview
    Table 46. Baxter International Primary Immunodeficiency Therapeutic Product
    Table 47. Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 48. Baxter International Recent Development
    Table 49. Takeda Pharmaceutical Company Detail
    Table 50. Takeda Pharmaceutical Business Overview
    Table 51. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product
    Table 52. Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 53. Takeda Pharmaceutical Recent Development
    Table 54. CSL Limited Company Detail
    Table 55. CSL Limited Business Overview
    Table 56. CSL Limited Primary Immunodeficiency Therapeutic Product
    Table 57. CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 58. CSL Limited Recent Development
    Table 59. Octapharma Company Detail
    Table 60. Octapharma Business Overview
    Table 61. Octapharma Primary Immunodeficiency Therapeutic Product
    Table 62. Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 63. Octapharma Recent Development
    Table 64. Kedrion Biopharma Company Detail
    Table 65. Kedrion Biopharma Business Overview
    Table 66. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product
    Table 67. Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 68. Kedrion Biopharma Recent Development
    Table 69. Bio Products Laboratory Company Detail
    Table 70. Bio Products Laboratory Business Overview
    Table 71. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product
    Table 72. Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 73. Bio Products Laboratory Recent Development
    Table 74. LFB group Company Detail
    Table 75. LFB group Business Overview
    Table 76. LFB group Primary Immunodeficiency Therapeutic Product
    Table 77. LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 78. LFB group Recent Development
    Table 79. Grifols Company Detail
    Table 80. Grifols Business Overview
    Table 81. Grifols Primary Immunodeficiency Therapeutic Product
    Table 82. Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 83. Grifols Recent Development
    Table 84. Lupin Pharmaceuticals Company Detail
    Table 85. Lupin Pharmaceuticals Business Overview
    Table 86. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product
    Table 87. Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
    Table 88. Lupin Pharmaceuticals Recent Development
    Table 89. Research Programs/Design for This Report
    Table 90. Key Data Information from Secondary Sources
    Table 91. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Primary Immunodeficiency Therapeutic Market Share by Type: 2021 VS 2028
    Figure 2. Immunoglobulin Replacement Therapy Features
    Figure 3. Stem Cell or Bone Marrow Transplantation Features
    Figure 4. Antibiotic Therapy Features
    Figure 5. Gene Therapy Features
    Figure 6. Others Features
    Figure 7. Global Primary Immunodeficiency Therapeutic Market Share by Application in 2021 & 2028
    Figure 8. Antibody Deficiency Case Studies
    Figure 9. Cellular Immunodeficiency Case Studies
    Figure 10. Innate Immune Disorders Case Studies
    Figure 11. Others Case Studies
    Figure 12. Primary Immunodeficiency Therapeutic Report Years Considered
    Figure 13. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 14. Global Primary Immunodeficiency Therapeutic Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Primary Immunodeficiency Therapeutic Market Share by Region: 2021 VS 2028
    Figure 16. Global Primary Immunodeficiency Therapeutic Market Share by Players in 2021
    Figure 17. Global Top Primary Immunodeficiency Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2021)
    Figure 18. The Top 10 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2021
    Figure 19. North America Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. North America Primary Immunodeficiency Therapeutic Market Share by Country (2017-2028)
    Figure 21. United States Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Primary Immunodeficiency Therapeutic Market Share by Country (2017-2028)
    Figure 25. Germany Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. France Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. U.K. Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Italy Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Russia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Nordic Countries Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Region (2017-2028)
    Figure 33. China Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Japan Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. South Korea Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Southeast Asia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. India Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Australia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Latin America Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Latin America Primary Immunodeficiency Therapeutic Market Share by Country (2017-2028)
    Figure 41. Mexico Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Brazil Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Middle East & Africa Primary Immunodeficiency Therapeutic Market Share by Country (2017-2028)
    Figure 45. Turkey Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Saudi Arabia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Baxter International Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 48. Takeda Pharmaceutical Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 49. CSL Limited Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 50. Octapharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 51. Kedrion Biopharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 52. Bio Products Laboratory Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 53. LFB group Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 54. Grifols Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 55. Lupin Pharmaceuticals Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
    Figure 58. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals
Frequently Asked Questions
Primary Immunodeficiency Therapeutic report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Primary Immunodeficiency Therapeutic report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Primary Immunodeficiency Therapeutic report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports